Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | FRK | P42685 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.44 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078199 | 0.88 | MAPK13 (0.40) | PTGS2MAP4K4MAPK9CSNK1A1CSNK1D | |
| SCHEMBL4073623 | 0.86 | DGAT1 (0.40) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL31469288 | 0.85 | DGAT1 (0.42) | PTGS2PRKD3MAP4K4FRKMAPK9 | |
| SCHEMBL1127963 | 0.82 | MAPK14 (0.64) | MAP4K4MAPK9CSNK1A1CSNK1DMAP4K5 | |
| SCHEMBL1127905 | 0.82 | MAPK14 (0.64) | MAP4K4MAPK9CSNK1A1CSNK1DMAP4K5 | |
| SCHEMBL4799247 | 0.82 | DGAT1 (0.41) | PTGS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4799731 | 0.82 | PTGS2 (0.43) | PTGS2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22862956 | 0.81 | DGAT1 (0.42) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL29490169 | 0.81 | DGAT1 (0.42) | PTGS2DGAT1 | |
| SCHEMBL11424185 | 0.78 | PTGS2 (0.54) | PTGS2PRKD3MAP4K4FRKMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7084155-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2006-08-01 | — | — | US | disclosed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
| US-5318984-A | Anticholesterol agents which inhibit acetyl coenzyme A transferase | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0372445-B1 | Imidazoles for the treatment of atherosclerosis | DU PONT MERCK PHARMA (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5166214-A | Enzyme inhibitors for anticholesterol agents, enzyme inhibitor and cardiovascular disorders | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-11-24 | — | — | US | disclosed |
| WO-1992005148-A1 | IMIDAZOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS | RHONE-POULENC RORER LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| WO-1991018885-A1 | IMIDAZOLES FOR THE TREATMENT OF ATHEROSCLEROSIS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0372445-A1 | Imidazoles for the treatment of atherosclerosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | PTGS2 2050/4885PRKD3 2042/4885MAP4K4 1617/4885 |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | PTGS2 2397/4885PRKD3 1893/4885MAP4K4 2305/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | PTGS2 2050/4885PRKD3 2042/4885MAP4K4 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.